MY8500747A - Aminoalkyl furan derivative - Google Patents

Aminoalkyl furan derivative

Info

Publication number
MY8500747A
MY8500747A MY747/85A MY8500747A MY8500747A MY 8500747 A MY8500747 A MY 8500747A MY 747/85 A MY747/85 A MY 747/85A MY 8500747 A MY8500747 A MY 8500747A MY 8500747 A MY8500747 A MY 8500747A
Authority
MY
Malaysia
Prior art keywords
furan derivative
aminoalkyl
aminoalkyl furan
derivative
furan
Prior art date
Application number
MY747/85A
Other languages
English (en)
Inventor
Derek Leslie Crookes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY8500747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY8500747A publication Critical patent/MY8500747A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
MY747/85A 1980-10-01 1985-12-30 Aminoalkyl furan derivative MY8500747A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01

Publications (1)

Publication Number Publication Date
MY8500747A true MY8500747A (en) 1985-12-31

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
MY747/85A MY8500747A (en) 1980-10-01 1985-12-30 Aminoalkyl furan derivative

Country Status (29)

Country Link
US (2) US4521431A (de)
JP (1) JPS5791983A (de)
KR (1) KR870001431B1 (de)
AT (1) AT389696B (de)
AU (1) AU549119B2 (de)
BE (1) BE890574A (de)
CA (1) CA1202638A (de)
CH (1) CH652122A5 (de)
CZ (1) CZ280885B6 (de)
DE (1) DE3139134A1 (de)
DK (2) DK167794B1 (de)
ES (1) ES505951A0 (de)
FR (1) FR2491067A1 (de)
GR (1) GR72499B (de)
HK (1) HK97985A (de)
IE (1) IE51604B1 (de)
IL (1) IL63968A (de)
IT (1) IT1143237B (de)
KE (1) KE3549A (de)
LU (1) LU83661A1 (de)
MY (1) MY8500747A (de)
NL (1) NL8104482A (de)
NZ (1) NZ198522A (de)
PH (2) PH19489A (de)
PT (1) PT73744B (de)
SE (1) SE453500B (de)
SK (1) SK277922B6 (de)
ZA (1) ZA816809B (de)
ZW (1) ZW24481A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88157C (fi) * 1983-07-15 1993-04-13 Richter Gedeon Vegyeszet Foerfarande foer framstaellning av vaetekloriden av 1- 2-/5-dimetylaminometyl-2-(furylmetyltio)-etyl/ -amino-1-metylamino-2-nitroetylen
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
DK0690864T3 (da) * 1993-03-12 2001-09-17 Upjohn Co Krystallinsk ceftiofur på fri syreform
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
US5670671A (en) * 1994-04-08 1997-09-23 Brantford Chemicals Inc. Process for the production of an improved form of form 1 ranitidine
ATE207481T1 (de) 1994-04-15 2001-11-15 Upjohn Co Kristallformen von 1-(5-methansulfonamidoindolyl- 2-carbonyl)-4-(3-(1-methylethylamino)-2- pyridinyl) piperazin
IN181698B (de) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181699B (de) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
AU693892B2 (en) * 1994-05-18 1998-07-09 Aventisub Ii Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0694540B1 (de) 1994-06-24 1998-08-19 Ranbaxy Laboratories Limited Verfahren zur Herstellung von Ranitidinhydrochlorid in der Kristallform 1
WO1996016055A1 (en) * 1994-11-18 1996-05-30 Pharmacia & Upjohn Company A new physically stable solid form of a fluoroquinolone
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
ATE207065T1 (de) 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) * 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
BR0315433A (pt) * 2002-11-08 2005-08-30 Dov Pharmaceutical Inc Polimorfos de cloridreto de bicifadine
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
AU2006275870B2 (en) 2005-07-27 2013-01-10 Otsuka America Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
CA2667416C (en) * 2006-10-20 2013-12-17 Scinopharm Singapore Pte, Ltd. Process for making crystalline anhydrous docetaxel
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
EP2727912B1 (de) 2011-06-30 2017-04-19 Toray Industries, Inc. Glycinderivatkristalle und ihre pharmazeutische verwendung
CN106432147B (zh) * 2015-05-26 2018-04-17 烟台市华文欣欣医药科技有限公司 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU7595581A (en) 1982-04-08
LU83661A1 (fr) 1983-06-08
PT73744A (en) 1981-10-01
CZ280885B6 (cs) 1996-04-17
GR72499B (de) 1983-11-15
IT1143237B (it) 1986-10-22
DE3139134C2 (de) 1990-04-19
IT8149407A0 (it) 1981-10-01
KR870001431B1 (ko) 1987-08-06
DE3139134A1 (de) 1982-05-19
JPS5791983A (en) 1982-06-08
KE3549A (en) 1985-08-16
FR2491067B1 (de) 1984-09-07
US4672133A (en) 1987-06-09
US4521431A (en) 1985-06-04
PH21761A (en) 1988-02-18
AU549119B2 (en) 1986-01-16
NL8104482A (nl) 1982-05-03
ES8301954A1 (es) 1983-01-01
KR830007070A (ko) 1983-10-14
DK167923B1 (da) 1994-01-03
SK403591A3 (en) 1995-08-09
HK97985A (en) 1985-12-13
AT389696B (de) 1990-01-10
ZA816809B (en) 1983-05-25
PH19489A (en) 1986-05-14
CZ403591A3 (en) 1994-01-19
BE890574A (fr) 1982-04-01
DK33792A (da) 1992-03-12
IE812287L (en) 1982-04-01
CA1202638A (en) 1986-04-01
IE51604B1 (en) 1987-01-21
CH652122A5 (fr) 1985-10-31
SE453500B (sv) 1988-02-08
SE8105812L (sv) 1982-04-02
DK436281A (da) 1982-04-02
JPH0443070B2 (de) 1992-07-15
ATA422281A (de) 1989-06-15
NZ198522A (en) 1985-07-12
DK33792D0 (da) 1992-03-12
IL63968A0 (en) 1981-12-31
SK277922B6 (en) 1995-08-09
PT73744B (en) 1983-10-31
IL63968A (en) 1985-10-31
DK167794B1 (da) 1993-12-13
FR2491067A1 (fr) 1982-04-02
ZW24481A1 (en) 1983-04-27
ES505951A0 (es) 1983-01-01

Similar Documents

Publication Publication Date Title
MY8500747A (en) Aminoalkyl furan derivative
GB2084580B (en) Aminoalkyl furan derivative
GB2079270B (en) Imidazo-rifamycin derivatives
JPS5785379A (en) 3-aryl-5-isothiazole derivative
JPS56150050A (en) Oxitocin derivative
GB2091719B (en) Benzofuran derivatives
JPS5781476A (en) Isooxazolylbenzamide derivative
GB2083462B (en) 2-thiopenem derivatives
GB2088365B (en) Moranoline derivative
GB2067989B (en) Bis-moranoline derivatives
PH18633A (en) Novel antrancyclinone derivative
GB2075499B (en) Nonaprenylamine derivatives
GB8324990D0 (en) 3-aminopropoxyphenyl derivatives
JPS577467A (en) Novel phenylpropargylamine derivative
GB8309645D0 (en) Furan derivatives
DE3165137D1 (en) Thiophene derivatives
GB2088379B (en) 1-phenethylimidazole derivatives
ZW9881A1 (en) Substituted phenoxyaminopropanol derivatives
JPS5793949A (en) Alpha-cyanophenoxybenzylamine derivative
GB2076815B (en) Aminophenylpyridine derivatives
GB2085882B (en) Aprosamine derivatives
GB2070589B (en) 7a1methoxycephalospin derivatives
GB2074165B (en) Nonaprenylamine derivatives
GB2076395B (en) Nonaprenylamine derivatives
JPS57118540A (en) Bis-aminomethyl-anthraquinone derivative